Synthetic Genetic Systems
  • SynGenSys
  • Technology
  • Applications
    • Gene Therapy
    • Biopharmaceutical Manufacturing
  • About
  • News
  • Contact Us
  • We are Hiring
Syngensys

Synthetic Genetic Systems for next generation biomedicines and bioprocesses

Overview

SynGenSys creates product-specific libraries of synthetic genetic parts for next-generation biomedicines and biomanufacturing processes. 

Our philosophy is simple: all products and production processes are unique. Therefore core genetic assemblies used for therapy or biomanufacturing should harbour custom synthetic DNA parts and circuits designed to be fit for a specific purpose.

 

  • Antibody
  • Trispecific Antibody
  • Virus

SynGenSys Technology Platform

Our platform technology harnesses years of research and development with bioindustrial partners. We engineer novel synthetic genetic parts from the ground-up, based on bioinformatic analysis of streams of genome-scale information pertinent to the biological system and user-defined design criteria.

Syngensys Technology Platform
Our Synthetic Design Cycle

Gene Therapy

DNA Engineering for Cell Type Specificity and Control:  Gene and Cell Therapy

Transfer of therapeutic DNA or mRNA into human cells and tissues underpins many new strategies to treat disease. However, precise targeting and control of gene expression remains a fundamental challenge. Our design systems create novel libraries of cell-type specific promoters with a minimised DNA footprint that provide user-defined control of therapeutic transgene expression

Synthetic promoter constructs individually transfected into five different mammalian cell types.  For each cell type reporter expression level is shown relative to that obtained using a CMV promoter.

Biopharmaceutical Manufacturing

DNA Engineering for Manufacturability: Biologics Production

Recombinant DNA constructs used to engineer a mammalian cell factory are at the core of a biomanufacturing process.

However, next generation protein biopharmaceuticals or gene therapies are inherently variable, can be difficult to manufacture and generic, one-size-fits-all genetic vectors cannot be optimal in all cases. Expanding the manufacturability design space, our platform creates new DNA parts that re-programme key synthetic processes to speed cellular production.
 

Synthetic promoter constructs transfected into CHO cells.  Protein expression levels using synthetic promoters are shown relative to those obtained using a CMV promoter.

Expand your Manufacturability Solution Space

Genetic parts within a genetic assembly significantly influence the rate of multiple dynamic cellular processes (e.g. transcription, translation, transduction) that can affect product manufacturability. We envisage that the genetic vector does not have to be a "one-size-fits-all" single option, but can be designed to be product-specific using discrete combinations of synthetic parts.
 

Our Team

  • David James

    David James

    Chief Scientific Officer

  • Adam Jones

    Adam Brown

    Chief Technology Officer

  • Abayomi Johnson

    Abayomi Johnson

    Senior DNA Engineer

  • Renata Caikauskaite

    Renata Caikauskaite

    Senior DNA Engineer

  • Clare Bowler

    Administration Manager

  • Molly Smith

    Molly Smith

    Cell Engineer

  • Pamela O’Neill

    Pamela O’Neill

    Cell Engineer

Join SynGenSys

We are a small, growing company at the interface of cell and molecular biology, informatics and engineering. We aim to create disruptive new solutions for design and manufacturing of next-generation medicines. If you have a passion for biological systems engineering and want to know more, contact us.

Contact Us

News

  • SynGenSys Ltd. and Takeda Ventures, Inc. announce a strategic collaboration aimed at the development of novel cell-type specific synthetic promoters to support development of Takeda’s pipeline of innovative cell and gene therapies.

    Professor David James, Chief Scientific Officer of SynGenSys: “This is an incredibly exciting opportunity for SynGenSys. We will work closely with Takeda to design new synthetic DNA components that provide targeted and controlled expression of therapeutic transgenes only where they are needed, avoiding non-specific cytotoxicity in non-diseased cells and tissues”.

    “Takeda has established a world-class network of collaborators including a research partnership with Syngensys, where we are jointly leveraging our expertise to construct precision targeted gene therapy,” said Dr Victor Stone, Senior Investment Director and Partner, Takeda Ventures Inc. “Our collaboration and investment in Syngensys enables Takeda’s capabilities in synthetic promoters to advance next-generation gene therapies.”.

    https://www.takeda.com/

    Takeda - Better Health, Brighter Future

    • 7

    • Feb ’22

Contact

SynGenSys Ltd. 5th Floor, 3 St. Paul’s Place, 129 Norfolk Street, Sheffield S1 2JE, United Kingdom

Contact Us
Website by Little Fire Digital
  • Website Terms of Use
  • GDPR & Privacy
  • Cookie Policy

© Syngensys Ltd 2022